A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung...

por Katakami, N., Felip, E., Spigel, D. R., Kim, J.-H., Olivo, M., Guo, M., Nokihara, H., Yang, J. C.-H., Iannotti, N., Satouchi, M., Barlesi, F.
Publicado 2017

Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations

por Solomon, B.J., Loong, H.H., Summers, Y., Thomas, Z.M., French, P., Lin, B.K., Sashegyi, A., Wolf, J., Yang, J.C.-H., Drilon, A.
Publicado 2022

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

por Lin, C-C, Su, W-C, Yen, C-J, Hsu, C-H, Su, W-P, Yeh, K-H, Lu, Y-S, Cheng, A-L, Huang, D C-L, Fritsch, H, Voss, F, Taube, T, Yang, J C-H
Publicado 2014

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

por Garrido, P., Adjei, A.A., Bajpai, J., Banerjee, S., Berghoff, A.S., Choo, S.P., Felip, E., Furness, A.J.S., Garralda, E., Haanen, J., Letsch, A., Linardou, H., Peters, S., Sessa, C., Tabernero, J., Tsang, J., Yang, J.C-.H., Garassino, M.C.
Publicado 2021

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

por Schuler, M., Yang, J. C.-H., Park, K., Kim, J.-H., Bennouna, J., Chen, Y.-M., Chouaid, C., De Marinis, F., Feng, J.-F., Grossi, F., Kim, D.-W., Liu, X., Lu, S., Strausz, J., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Chand, V. K., Planchard, D.
Publicado 2016

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

por Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.
Publicado 2017

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

por Berghoff, A.S., Sessa, C., Yang, J.C.-H., Tsourti, Z., Tsang, J., Tabernero, J., Peters, S., Linardou, H., Letsch, A., Haanen, J., Garralda, E., Garassino, M.C., Furness, A.J.S., Felip, E., Dimopoulou, G., Dafni, U., Choo, S.P., Banerjee, S., Bajpai, J., Adjei, A.A., Garrido, P.
Publicado 2021

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

por Linardou, H., Adjei, A.A., Bajpai, J., Banerjee, S., Berghoff, A.S., Mathias, C. Cerqueira, Choo, S.P., Dent, R., Felip, E., Furness, A.J.S., Garassino, M.C., Garralda, E., Konsoulova-Kirova, A., Letsch, A., Menzies, A.M., Mukherji, D., Peters, S., Sessa, C., Tsang, J., Yang, J.C.-H., Garrido, P.
Publicado 2023